A Double Blind, Randomized, Placebo Controlled, Multicenter Study Examining the Efficacy and Safety of SEP-225441 in Subjects With Generalized Anxiety Disorder.
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2016
At a glance
- Drugs Eszopiclone (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 18 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 06 Mar 2009 Preliminary results were reported in a media release, dated 6 March 2009 [www.sepracor.com].
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History